Analysts expect Allogene Therapeutics to post earnings of ($0.1714) per share and revenue of $0.0020 million for the quarter. Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its earnings results on Wednesday, May 13th. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. Get Allogene Therapeutics alerts:Allogene Therapeutics Stock PerformanceALLO stock opened at $1.90 on Wednesday. Further ReadingReceive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.